We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M
Read MoreHide Full Article
Key Takeaways
Esperion will acquire Corstasis for $75M upfront in cash, plus up to $180M in certain milestones.
The deal adds FDA-approved Enbumyst, a nasal spray diuretic for edema in CHF and liver and kidney disease.
Esperion expects the buyout to strengthen its cardiovascular franchise and drive double-digit revenue growth.
Esperion Therapeutics (ESPR - Free Report) announced that it has entered into a definitive agreement to acquire Nevada-based, privately held, commercial-stage biopharmaceutical company, Corstasis Therapeutics, for up to $75 million in cash.
The impending acquisition will add Corstasis’ lead product, Enbumyst (bumetanide nasal spray), to Esperion’s commercial portfolio, which is expected to strengthen and expand the company’s cardiovascular franchise.
Enbumyst is the first and only nasal spray diuretic approved by the FDA for the treatment of edema associated with congestive heart failure (CHF) and hepatic and renal disease in adults.
The transaction is expected to be closed in the second quarter of 2026, subject to customary closing conditions.
Shares of Esperion were down 11% yesterday following the announcement of the news.
Year to date, shares of Esperion have plunged 21.4% against the industry’s increase of 2%.
Image Source: Zacks Investment Research
ESPR’s Deal Rationale
Per the latest deal, Esperion, through a subsidiary, will acquire all outstanding shares of Corstasis for an upfront payment of $75 million in cash. Corstasis is also eligible to receive up to an additional $180 million if certain regulatory and sales milestones are achieved, along with low double-digit royalties on net sales of Enbumyst.
The deal appears to be a strong strategic fit for Esperion, as it should enhance its cardiovascular platform, broaden its commercial portfolio, and accelerate double-digit revenue growth.
Enbumyst is a differentiated, self-administered outpatient diuretic that can help bridge the gap between oral and IV diuretic therapies for patients with edema related to CHF, liver disease and kidney disease.
Esperion will fund the acquisition using its existing credit facilities and by monetizing its Japanese royalties through funds managed by Athyrium Capital Management and HealthCare Royalty.
ESPR Aims to Boost Cardiovascular Franchise
Esperion has two FDA-approved drugs in its commercial portfolio, Nexletol (bempedoic acid) and Nexlizet, which are approved for treating elevated LDL-C (bad cholesterol) and for cardiovascular risk reduction. Nexlizet is a combination of bempedoic acid and ezetimibe.
These two oral drugs are marketed as Nilemdo and Nustendi in ex-U.S. markets (excluding Japan, where the company has a collaboration with Otsuka Pharmaceuticals) in partnership with Daiichi Sankyo. The company records royalties on sales of its drugs in ex-U.S. markets.
Net product sales of Nexletol and Nexlizet in the United States grew 38% in the first nine months of 2025 to $115.8 million, reflecting increased prescription growth volumes.
Per management, the addition of Enbumyst through the acquisition of Corstasis is likely to help Esperion target a potential market opportunity of more than $4 billion in the United States.
The deal is well aligned with Esperion’s recently introduced Vision 2040.
ESPR's Zacks Rank & Stocks to Consider
Esperion currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the drug/biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) , ANI Pharmaceuticals (ANIP - Free Report) and Replimune Group (REPL - Free Report) . While Catalyst Pharmaceuticals currently sports a Zacks Rank #1 (Strong Buy), ANI Pharmaceuticals and Replimune hold a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have increased from $2.54 to $2.59, while the same for 2027 have increased from $2.85 to $3.01. CPRX’s shares have risen 2.5% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 earnings per share have increased from $8.08 to $8.22, while the same for 2027 have increased from $9.25 to $9.90. ANIP’s shares have fallen 3.6% year to date.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Over the past 60 days, Replimune’s 2026 loss per share estimates have narrowed from $3.59 to $3.41, while the same for 2027 have narrowed from $2.42 to $2.33. REPL’s shares have plunged 26.2% year to date.
Replimune’s earnings beat estimates in one of the trailing four quarters and missed on the remaining three occasions, with the average negative surprise being 4.46%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M
Key Takeaways
Esperion Therapeutics (ESPR - Free Report) announced that it has entered into a definitive agreement to acquire Nevada-based, privately held, commercial-stage biopharmaceutical company, Corstasis Therapeutics, for up to $75 million in cash.
The impending acquisition will add Corstasis’ lead product, Enbumyst (bumetanide nasal spray), to Esperion’s commercial portfolio, which is expected to strengthen and expand the company’s cardiovascular franchise.
Enbumyst is the first and only nasal spray diuretic approved by the FDA for the treatment of edema associated with congestive heart failure (CHF) and hepatic and renal disease in adults.
The transaction is expected to be closed in the second quarter of 2026, subject to customary closing conditions.
Shares of Esperion were down 11% yesterday following the announcement of the news.
Year to date, shares of Esperion have plunged 21.4% against the industry’s increase of 2%.
Image Source: Zacks Investment Research
ESPR’s Deal Rationale
Per the latest deal, Esperion, through a subsidiary, will acquire all outstanding shares of Corstasis for an upfront payment of $75 million in cash. Corstasis is also eligible to receive up to an additional $180 million if certain regulatory and sales milestones are achieved, along with low double-digit royalties on net sales of Enbumyst.
The deal appears to be a strong strategic fit for Esperion, as it should enhance its cardiovascular platform, broaden its commercial portfolio, and accelerate double-digit revenue growth.
Enbumyst is a differentiated, self-administered outpatient diuretic that can help bridge the gap between oral and IV diuretic therapies for patients with edema related to CHF, liver disease and kidney disease.
Esperion will fund the acquisition using its existing credit facilities and by monetizing its Japanese royalties through funds managed by Athyrium Capital Management and HealthCare Royalty.
ESPR Aims to Boost Cardiovascular Franchise
Esperion has two FDA-approved drugs in its commercial portfolio, Nexletol (bempedoic acid) and Nexlizet, which are approved for treating elevated LDL-C (bad cholesterol) and for cardiovascular risk reduction. Nexlizet is a combination of bempedoic acid and ezetimibe.
These two oral drugs are marketed as Nilemdo and Nustendi in ex-U.S. markets (excluding Japan, where the company has a collaboration with Otsuka Pharmaceuticals) in partnership with Daiichi Sankyo. The company records royalties on sales of its drugs in ex-U.S. markets.
Net product sales of Nexletol and Nexlizet in the United States grew 38% in the first nine months of 2025 to $115.8 million, reflecting increased prescription growth volumes.
Per management, the addition of Enbumyst through the acquisition of Corstasis is likely to help Esperion target a potential market opportunity of more than $4 billion in the United States.
The deal is well aligned with Esperion’s recently introduced Vision 2040.
ESPR's Zacks Rank & Stocks to Consider
Esperion currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the drug/biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) , ANI Pharmaceuticals (ANIP - Free Report) and Replimune Group (REPL - Free Report) . While Catalyst Pharmaceuticals currently sports a Zacks Rank #1 (Strong Buy), ANI Pharmaceuticals and Replimune hold a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have increased from $2.54 to $2.59, while the same for 2027 have increased from $2.85 to $3.01. CPRX’s shares have risen 2.5% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 earnings per share have increased from $8.08 to $8.22, while the same for 2027 have increased from $9.25 to $9.90. ANIP’s shares have fallen 3.6% year to date.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Over the past 60 days, Replimune’s 2026 loss per share estimates have narrowed from $3.59 to $3.41, while the same for 2027 have narrowed from $2.42 to $2.33. REPL’s shares have plunged 26.2% year to date.
Replimune’s earnings beat estimates in one of the trailing four quarters and missed on the remaining three occasions, with the average negative surprise being 4.46%.